Sermorelin

Category: peptide

Aliases: GHRH(1-29), GRF(1-29)NH₂, Geref

Pharmacological Mechanism

Truncated 29-residue N-terminal fragment of native GHRH — retains full GH-releasing activity. Binds GHRH-R on somatotrophs → cAMP rise → GH release. Preserves physiologic negative-feedback loop (unlike direct HGH injection) so overtreatment risk is lower. Very short plasma t½ (~11 min) — divided or evening dosing.

Half-Life (t½)

SC: 0.07h

Dosing Guidelines

• SC: Typical 300 mcg (Range: 200–500 mcg)

Target Organ Systems

• endocrine
• musculoskeletal

Interactions

• Ipamorelin (synergistic): GHRH (sermorelin) + ghrelin mimetic (ipamorelin) together amplify GH pulse >2× either alone — classic 'GHRH + GHRP' stack.

Pathways It Modulates

• Growth hormone / GHRH / GHS axis (activator) — GHRH-R

Chemical Identifiers

• PubChem CID: 16132413
• Formula: C149H246N44O42S
• Molecular weight: 3357.9 g/mol
• InChIKey: WGWPRVFKDLAUQJ-MITYVQBRSA-N
• SMILES: CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC3=CC=C(C=C3)O)N

References

• PMID 7962295